Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | GNA15 | P30679 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6690731 | 0.83 | CA1 (0.54) | MAOBPPARA | |
| SCHEMBL18639194 | 0.82 | CACNA1B (0.65) | CACNA1BFFAR1PPARAGNA15PTGER3 | |
| SCHEMBL7995375 | 0.82 | CA1 (0.59) | FFAR1MAOBHTT | |
| SCHEMBL15474248 | 0.80 | CACNA1B (0.62) | CACNA1BFFAR1FAAHGNA15PTGER3 | |
| SCHEMBL5178370 | 0.80 | FFAR1 (0.58) | CACNA1BFFAR1GNA15PTGER3FFAR4 | |
| SCHEMBL30679029 | 0.77 | HTT (0.49) | FFAR1HTT | |
| SCHEMBL12957071 | 0.77 | HTT (0.49) | FFAR1HTT | |
| SCHEMBL15472298 | 0.77 | FFAR1 (0.59) | CACNA1BFFAR1PPARAKDM4EALDH1A1 | |
| SCHEMBL1241386 | 0.77 | CA1 (0.48) | FFAR1MAOBPPARAFFAR4SMN1; SMN2 | |
| SCHEMBL13676154 | 0.76 | RAB9A (0.65) | FFAR1FAAHALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | claimed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| EP-2049493-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | Cadila Healthcare Limited (IN) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CETP, APOB, HDLBP | CACNA1B 4598/4885FFAR1 310/4885MAOB 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.